IRIS
PASSAMONTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.229
AS - Asia 3.170
EU - Europa 2.549
SA - Sud America 346
AF - Africa 94
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 7
Totale 10.403
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.136
CN - Cina 1.611
SG - Singapore 641
IE - Irlanda 500
UA - Ucraina 384
HK - Hong Kong 360
FI - Finlandia 296
DE - Germania 282
VN - Vietnam 243
BR - Brasile 240
RU - Federazione Russa 238
FR - Francia 218
IT - Italia 204
SE - Svezia 152
GB - Regno Unito 138
IN - India 76
CA - Canada 45
BD - Bangladesh 44
ZA - Sudafrica 37
AR - Argentina 36
MX - Messico 35
NL - Olanda 31
PK - Pakistan 31
PL - Polonia 26
IQ - Iraq 24
JP - Giappone 22
EC - Ecuador 18
CO - Colombia 16
BE - Belgio 15
TR - Turchia 14
SA - Arabia Saudita 13
ES - Italia 11
ID - Indonesia 11
VE - Venezuela 11
JO - Giordania 10
MY - Malesia 10
PY - Paraguay 10
AT - Austria 9
LT - Lituania 9
PH - Filippine 8
TN - Tunisia 8
AU - Australia 7
CL - Cile 7
MA - Marocco 7
MU - Mauritius 7
EU - Europa 6
KE - Kenya 6
NP - Nepal 6
UZ - Uzbekistan 6
AL - Albania 5
CZ - Repubblica Ceca 5
EG - Egitto 5
CH - Svizzera 4
DZ - Algeria 4
GA - Gabon 4
GR - Grecia 4
NG - Nigeria 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
ET - Etiopia 3
IL - Israele 3
IR - Iran 3
JM - Giamaica 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
PA - Panama 3
RO - Romania 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LV - Lettonia 2
LY - Libia 2
OM - Oman 2
QA - Qatar 2
RS - Serbia 2
SN - Senegal 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GE - Georgia 1
HU - Ungheria 1
JE - Jersey 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
Totale 10.393
Salva come PNG Salva come JPEG
Città #
Chandler 548
Dublin 500
Jacksonville 470
San Jose 370
Hong Kong 356
Nanjing 352
Singapore 324
Ashburn 315
Dallas 296
Beijing 254
Boardman 191
Lauterbourg 167
Nanchang 135
Los Angeles 118
Hebei 116
Princeton 112
Shenyang 109
Lawrence 108
Medford 102
Wilmington 102
New York 101
Changsha 99
Ann Arbor 84
Ho Chi Minh City 82
Jiaxing 69
Helsinki 64
Tianjin 62
Hanoi 55
Hangzhou 54
Council Bluffs 46
Munich 42
Buffalo 41
Milan 39
Shanghai 38
Woodbridge 38
Orem 36
Santa Clara 35
Moscow 34
Redondo Beach 34
Johannesburg 29
Warsaw 22
Tokyo 21
Turku 20
Rome 18
San Francisco 17
Norwalk 16
São Paulo 16
Verona 16
Brussels 15
Chennai 15
Rawalpindi 15
Toronto 15
Des Moines 14
Fairfield 13
Nuremberg 13
Pavia 13
Da Nang 12
Falkenstein 12
Manchester 12
Mexico City 12
Seattle 12
The Dalles 12
Auburn Hills 11
Montreal 11
Baghdad 10
Frankfurt am Main 10
Hải Dương 10
Stockholm 10
Amman 9
Atlanta 9
Boston 9
Brooklyn 9
Denver 9
Florence 9
Guayaquil 9
Jinan 9
Kunming 9
Phoenix 9
Poplar 9
Guangzhou 8
New Delhi 8
Ningbo 8
Pune 8
Rio de Janeiro 8
Riyadh 8
Zhengzhou 8
Amsterdam 7
Genoa 7
Haiphong 7
Istanbul 7
London 7
Taizhou 7
Chicago 6
Falls Church 6
Houston 6
Kuala Lumpur 6
Lanzhou 6
Phủ Lý 6
Tappahannock 6
Vienna 6
Totale 6.765
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 188
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 179
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 155
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 147
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 145
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 142
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 142
Blast phase of essential thrombocythemia: A single center study. 138
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 135
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 132
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 130
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS 129
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons 129
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients 128
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 128
A gain-of-function mutation of JAK2 in myeloproliferative disorders 125
Clinical Predictors of Outcome in MPN. 124
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 119
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 118
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 117
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA 116
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process 114
Looking for CALR mutations in familial myeloproliferative neoplasms 111
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. 110
JAK2 (V617F) mutation in healthy individuals 109
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 109
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA 107
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy 107
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 107
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 107
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 106
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 106
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 106
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 105
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 104
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report 103
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 102
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 102
Leukemia risk models in primary myelofibrosis: an International Working Group study. 100
Balancing efficacy and safety of JAK inhibitors in myelofibrosis 100
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 99
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 98
Clinical relevance of JAK2 (V617F) mutant allele burden 96
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs 95
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 95
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 94
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history 93
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases 92
Pomalidomide is active in the treatment of anemia associated with myelofibrosis 91
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. 90
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY 90
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 89
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera 89
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 89
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 89
PDGFRB disease: right diagnosis to prolong survival 88
New generation small-molecule inhibitors in myeloproliferative neoplasms 88
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 87
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 87
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 87
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies 87
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients 87
Leucemia mieloide cronica e sindromi mieloproliferative croniche 86
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. 86
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. 86
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders 86
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 85
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. 85
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma 85
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. 85
How I treat polycythemia vera. 84
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases 82
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project 82
How to manage polycythemia vera 81
Myeloproliferative Neoplasms 81
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment 80
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis 79
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. 78
Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients 77
What are RBC-transfusion-dependence and -independence? 76
LE NEOPLASIE MIELOPROLIFERATIVE PHILADELPHIA NEGATIVE 76
RBC-transfusion guidelines update 75
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 75
Mutational status of myeloproliferative neoplasms. 74
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper 74
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients 74
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. 74
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN. 73
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 73
Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection 72
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. 72
Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi 71
Ruxolitinib and survival improvement in patients with myelofibrosis 71
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 71
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 71
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 70
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. 68
It is time to change thrombosis risk assessment for PV and ET? 68
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy 67
Disease anticipation in familial myeloproliferative neoplasms. 67
Totale 9.801
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.497
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.497
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202121 0 0 0 0 0 0 0 0 0 0 0 21
2021/2022493 11 6 11 6 19 11 6 29 21 17 82 274
2022/20231.573 168 96 18 149 150 180 2 102 632 11 32 33
2023/2024537 79 92 16 48 34 157 3 33 4 11 15 45
2024/20251.427 29 127 36 39 40 66 43 117 335 34 229 332
2025/20263.531 280 335 413 347 355 237 663 134 336 273 102 56
Totale 10.518